Collaboration on the Optimization of Macromolecular Pharmaceutical Access to Cellular Targets (COMPACT)

At a Glance
  • Status: Active Consortium
  • Year Launched: 2012
  • Initiating Organization: Innovative Medicines Initiative
  • Initiator Type: Government
  • No disease focus
  • Location: Europe


Many new medicines are based on biological molecules such as proteins, peptides, or nucleic acids. The goal of the Collaboration on the Optimization of Macromolecular Pharmaceutical Access to Cellular Targets (COMPACT) project is to shed new light on the obstacles these drugs (which are known as biopharmaceuticals) need to overcome to get to where they are needed in the body. The team will then use this information to develop and validate biopharmaceutical formulations to deliver these novel drugs to their targets. The program duration is set at 60 months.


COMPACT's overall objective is to reduce delivery and targeting bottlenecks for developing novel, innovative, biopharmaceutical-based medicines.

Consortium History

Nov. 1, 2012: COMPACT was officially launched.

Structure & Governance

The COMPACT team is coordinated by Sanofi, GSK, and Universiteit Utrecht.


COMPACT is funded by the Innovative Medicines Initiative (IMI; €10.2 million) as well as the European Federation of Pharmaceutical Industries and Associations (€16.6 million in kind, including €1.6 million of non-European Union contributions), and academic institutions and other contributors (€3.2 million). The list of funders can be found at

Intellectual Property

The IMI intellectual property (IP) policy governs the IP regime of all projects funded by the IMI Joint Undertaking. To assist with specific IP queries, IMI has set up a dedicated IP Helpdesk, which can be contacted by emailing IMI-IP-Helpdesk[AT] The IMI IP policy can be accessed at

Data Sharing

In keeping with IMI policy, the COMPACT project has up to one year after completion to disseminate IP or data created by the project.


COMPACT believes that biopharmaceuticals have the potential to improve the lives of patients with diseases and conditions that are currently hard or even impossible to treat. By finding more effective ways of administering these drugs, and improving their ability to travel through the body to where they are needed, COMPACT will enable more patients to benefit from biopharmaceuticals. Furthermore, designing less-invasive administration routes and reducing the dose (and therefore the side effects) and frequency of administration will help to improve patient compliance with treatments.

The 2013 award for Hungarian Young Entrepreneur of the Year was won by Tamas Letoha, chief executive officer of Pharmacoidea, which is a partner in two IMI projects: COMPACT and AETIONOMY.

Points of Contact

Ekkehard Leberer
Sanofi-Aventis Deutschland GmbH
phone: +49 69 305 18998

Enrico Mastrobattista
Universiteit Utrecht
phone: +31 6 22736567

Sponsors & Partners

Abbott GmbH & CoKG

Bioneer A/S

Boehringer Ingelheim International GmbH

Cardiff University

GlaxoSmithKline Research and Development Ltd.

Helmholtz-Zentrum für Infektionsforschung GmbH

Helsingin Yliopisto

Ludwig-Maximilians-Universität München

Merck KGaA

Norges Teknisk-Naturvitenskapelige Universitet NTNU

Novo Nordisk A/S

Pfizer Limited

Pharmacoidea Development and Service Ltd

Sanofi-Aventis Deutschland GmbH

Stockholms Universitet

Universität Wien

Universität Zurich            

Universiteit Gent

Universiteit Leiden

Universiteit Utrecht

University of Copenhagen

University of Oxford

Last Updated: 04/14/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.